Rayliant Investment Research Invitae Corp Transaction History
Rayliant Investment Research
- $101 Billion
- Q4 2022
A detailed history of Rayliant Investment Research transactions in Invitae Corp stock. As of the latest transaction made, Rayliant Investment Research holds 50,388 shares of NVTA stock, worth $0. This represents 0.09% of its overall portfolio holdings.
Number of Shares
50,388Holding current value
$0% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding NVTA
# of Institutions
20Shares Held
1.92MCall Options Held
0Put Options Held
0-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA1.28MShares$02.19% of portfolio
-
Alphabet Inc. Mountain View, CA236KShares$00.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ158KShares$00.0% of portfolio
-
Eaton Vance Management Boston, MA100KShares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY47.8KShares$00.0% of portfolio
About Invitae Corp
- Ticker NVTA
- Exchange NYSE
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 235,266,000
- Description
- Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...